ArticleGeroScience2026
Longitudinal lipidomic markers of cardiac aging and risk of coronary heart disease in American Indians: the Strong Heart Family Study.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Age-related decline in left ventricular (LV) diastolic function is a hallmark of cardiac aging and an early precursor to cardiovascular disease. While dyslipidemia is a known driver of coronary heart disease (CHD), the molecular pathways linking lipid metabolism to cardiac aging and subsequent CHD risk remain poorly understood. Furthermore, longitudinal lipidomic profiling of cardiac aging in large human populations has not been systematically conducted. Using an untargeted LC-MS, we repeatedly measured 1542 fasting plasma lipid species in 1801 American Indians across two clinical exams in the Strong Heart Family Study (SHFS) (mean age at baseline: 40.0 years; mean interval: 5.5 years apart). We examined longitudinal associations between individual lipid species and measures of cardiac aging (E/A ratio, isovolumic relaxation time, and deceleration time) using generalized estimation equation (GEE), adjusted for demographic, lifestyle, and clinical factors. Significant associations were then replicated in the Bogalusa Heart Study (BHS) (mean age at baseline: 48.1 years). Frailty Cox proportional hazards models were used to examine whether cardiac aging-related lipids predicted incident CHD over a 20-year follow-up. We found that multiple lipid species, primarily glycerophospholipids, glycerolipids, and sphingomyelins, were associated with measures of cardiac aging, with the majority showing inverse associations. Some of these associations were confirmed in a biracial cohort of African American and White participants. Additionally, baseline levels of specific glycerophospholipids and fatty acids associated with diastolic function (E/A ratio and deceleration time) were linked to a reduced risk of CHD (HR range: 0.21-0.86). Conversely, other E/A-associated glycerophospholipids were linked to increased CHD risk (HR range: 1.24-1.34). In summary, we identified distinct lipidomic signatures associated with trajectories of subclinical cardiac aging, several of which also predict later-life CHD risk. These findings highlight molecular correlates of cardiac aging from midlife into older adulthood and suggest that lipidomic pathways may serve as early biomarkers for future: Keywords are required, The following are suggested: "Cardiac aging, Risk, Lipidomic markers". Please check if correct. CHD.
Indexed as
Identifiers
42387180What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.